Payment overview · 2025
General Payments
$4,108.25
162 reported records · 33 companies
Healthcare provider profile · identity verified
Gary Reznik, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · LOS ANGELES, CA · NPI 1043244296
Verified facts
What the public records show
CMS Open Payments records show Gary Reznik, MD received $4,108.25 in general payments during 2025 across 162 reported records.
E.R. Squibb & Sons, L.L.C. accounted for 10.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 48 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Brilinta, Creon, Eliquis, Farxiga, Gemtesa, Jardiance, Kerendia, Linzess, Mounjaro, Nurtec Odt, Ozempic, Paxlovid, Trelegy Ellipta, Trintellix, Veltassa, Verquvo, Wegovy, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 300 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 283 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 397 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Zenpep by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 185 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 246 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TUDORZA PRESSAIR as an associated drug or biological on 89 records involving 63 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Tudorza Pressair by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 321 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synjardy by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 352 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 1509 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 321 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 1751 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trulicity by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Verquvo by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 744 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 614 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 352 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Gemtesa by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Trintellix by this doctor in 2024.
Vifor Pharma, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Veltassa as an associated drug or biological on 5970 records involving 2480 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Veltassa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $410.22 | 10.0% | 23 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$377.22 | 9.2% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $339.95 | 8.3% | 14 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $292.75 | 7.1% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $286.20 | 7.0% | 14 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $244.59 | 6.0% | 11 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $205.09 | 5.0% | 6 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $183.26 | 4.5% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $171.04 | 4.2% | 7 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $168.37 | 4.1% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $157.39 | 3.8% | 7 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $157.33 | 3.8% | 8 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $140.66 | 3.4% | 8 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $124.08 | 3.0% | 5 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $107.59 | 2.6% | 4 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $87.57 | 2.1% | 3 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $75.07 | 1.8% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $62.46 | 1.5% | 3 | 2025 |
| Vifor Pharma, Inc. | Unresolved — no canonical attribution shown | $57.10 | 1.4% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $52.22 | 1.3% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $50.05 | 1.2% | 2 | 2025 |
| VIVUS LLC | Unresolved — no canonical attribution shown | $48.77 | 1.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $47.25 | 1.1% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $45.32 | 1.1% | 2 | 2025 |
| Avanos Medical | Unresolved — no canonical attribution shown | $34.69 | 0.8% | 2 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.83 | 0.8% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $28.76 | 0.7% | 1 | 2025 |
| Invivyd Inc | Unresolved — no canonical attribution shown | $24.68 | 0.6% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $21.83 | 0.5% | 1 | 2025 |
| DePuy Synthes Sales Inc. | Unresolved — no canonical attribution shown | $21.33 | 0.5% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $19.09 | 0.5% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $17.47 | 0.4% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $17.02 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,108.25 | 162 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $339.95 | 14 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $275.70 | 14 | 2025 |
Source payment records
|
|||||
| MYCARELINK Normalized: mycarelink |
Device | Medtronic, Inc. | $275.26 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $231.01 | 9 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $205.09 | 6 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $183.26 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $175.63 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $174.45 | 8 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $168.37 | 6 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $161.70 | 10 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $157.33 | 8 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $156.85 | 7 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $140.66 | 8 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $140.66 | 8 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $140.66 | 8 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $124.08 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $118.99 | 5 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $111.75 | 6 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $107.59 | 4 | 2025 |
Source payment records
|
|||||
| AURORA EV-ICD MRI SURESCAN Normalized: aurora ev icd mri surescan |
Device | Medtronic, Inc. | $101.96 | 1 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $87.57 | 3 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $75.07 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $70.92 | 3 | 2025 |
Source payment records
|
|||||
| Veltassa Normalized: veltassa |
Drug | Vifor Pharma, Inc. | $57.10 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $52.22 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $52.05 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $50.05 | 2 | 2025 |
Source payment records
|
|||||
| PANCREAZE Normalized: pancreaze |
Drug | VIVUS LLC | $48.77 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $47.25 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $47.25 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $45.32 | 2 | 2025 |
Source payment records
|
|||||
| BRILINTA Normalized: brilinta |
Drug | AstraZeneca Pharmaceuticals LP | $37.27 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $35.28 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $35.28 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $31.94 | 2 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $31.83 | 1 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $28.76 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $26.67 | 1 | 2025 |
Source payment records
|
|||||
| PEMGARDA Normalized: pemgarda |
Biological | Invivyd Inc | $24.68 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $24.46 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $22.53 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $21.83 | 1 | 2025 |
Source payment records
|
|||||
| MONOVISC Normalized: monovisc |
Device | DePuy Synthes Sales Inc. | $21.33 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $19.09 | 1 | 2025 |
Source payment records
|
|||||
| TRIVISC SODIUM HYALURONATE Normalized: trivisc sodium hyaluronate |
Device | Avanos Medical | $17.91 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $17.47 | 1 | 2025 |
Source payment records
|
|||||
| Actemra Normalized: actemra |
Biological | Genentech USA, Inc. | $17.02 | 1 | 2025 |
Source payment records
|
|||||
| GENVISC 850 SODIUM HYALURONATE Normalized: genvisc 850 sodium hyaluronate |
Device | Avanos Medical | $16.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BRILINTA brilinta |
2025 | Brilinta | 2024 | 185 | exact normalized | Medicare Part D |
| CREON creon |
2025 | Creon | 2024 | 300 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 352 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 246 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 321 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 283 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 1751 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 614 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 21 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 145 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 59 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Veltassa veltassa |
2025 | Veltassa | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 106 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 47 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
300 | 33 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
283 | 39 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
397 | 44 |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
185 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
246 | 41 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | TUDORZA PRESSAIR open payments reported associated product |
CMS Open Payments — General Payments 89 supporting records · 63 recipient NPIs · example record 1206133584 |
Tudorza Pressair · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
321 | 49 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
352 | 47 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
145 | 20 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
1509 | 160 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
321 | 49 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
1751 | 214 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
106 | 12 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
744 | 77 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
614 | 72 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
160 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
47 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
352 | 47 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
21 | 20 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| Vifor Pharma, Inc. Exact reporting entity; no affiliate inference |
2025 | Veltassa open payments reported associated product |
CMS Open Payments — General Payments 5970 supporting records · 2480 recipient NPIs · example record 1172020739 |
Veltassa · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 3161 | 435 |
| Nebivolol Hcl | Nebivolol Hcl | 3102 | 348 |
| Edarbi | Azilsartan Medoxomil | 2142 | 239 |
| Hydralazine Hcl | Hydralazine Hcl | 1978 | 226 |
| Icosapent Ethyl | Icosapent Ethyl | 1850 | 252 |
| Mounjaro | Tirzepatide | 1751 | 214 |
| Pitavastatin Calcium | Pitavastatin Calcium | 1564 | 205 |
| Metoprolol Succinate | Metoprolol Succinate | 1554 | 186 |
| Xarelto | Rivaroxaban | 1509 | 160 |
| Vascepa | Icosapent Ethyl | 1469 | 201 |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 1144 | 131 |
| Amiodarone Hcl | Amiodarone Hcl | 1126 | 126 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 1048 | 169 |
| Repatha Sureclick | Evolocumab | 999 | 112 |
| Levothyroxine Sodium | Levothyroxine Sodium | 964 | 112 |
| Dexlansoprazole Dr | Dexlansoprazole | 901 | 100 |
| Furosemide | Furosemide | 811 | 101 |
| Entresto | Sacubitril/Valsartan | 744 | 77 |
| Amlodipine Besylate | Amlodipine Besylate | 700 | 99 |
| Ozempic | Semaglutide | 614 | 72 |
| Ezetimibe | Ezetimibe | 585 | 88 |
| Spironolactone | Spironolactone | 558 | 76 |
| Escitalopram Oxalate | Escitalopram Oxalate | 521 | 84 |
| Livalo | Pitavastatin Calcium | 467 | 75 |
| Carvedilol | Carvedilol | 442 | 52 |
| Atorvastatin Calcium | Atorvastatin Calcium | 433 | 70 |
| Synthroid | Levothyroxine Sodium | 397 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 387 | 48 |
| Allopurinol | Allopurinol | 377 | 60 |
| Eliquis | Apixaban | 352 | 47 |
| Doxazosin Mesylate | Doxazosin Mesylate | 349 | 50 |
| Potassium Chloride | Potassium Chloride | 348 | 42 |
| Jardiance | Empagliflozin | 321 | 49 |
| Dapagliflozin | Dapagliflozin Propanediol | 312 | 44 |
| Bystolic | Nebivolol Hcl | 303 | 39 |
| Creon | Lipase/Protease/Amylase | 300 | 33 |
| Linzess | Linaclotide | 283 | 39 |
| Tradjenta | Linagliptin | 279 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 249 | 35 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 248 | 26 |
| Farxiga | Dapagliflozin Propanediol | 246 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 246 | 39 |
| Omeprazole | Omeprazole | 234 | 36 |
| Propranolol Hcl Er | Propranolol Hcl | 228 | 24 |
| Metformin Hcl | Metformin Hcl | 224 | 34 |
| Febuxostat | Febuxostat | 212 | 27 |
| Telmisartan | Telmisartan | 193 | 25 |
| Lorazepam | Lorazepam | 190 | 36 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 187 | 29 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 187 | 28 |
| Brilinta | Ticagrelor | 185 | 21 |
| Clonazepam | Clonazepam | 185 | 23 |
| Ibandronate Sodium | Ibandronate Sodium | 167 | 25 |
| Silodosin | Silodosin | 162 | 19 |
| Rybelsus | Semaglutide | 160 | 26 |
| Lidocaine | Lidocaine | 159 | 21 |
| Valsartan | Valsartan | 158 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 154 | 19 |
| Nitroglycerin | Nitroglycerin | 149 | 27 |
| Dayvigo | Lemborexant | 148 | 30 |
| Meclizine Hcl | Meclizine Hcl | 147 | 21 |
| Tadalafil | Tadalafil | 146 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 145 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 141 | 15 |
| Famotidine | Famotidine | 138 | 16 |
| Atenolol | Atenolol | 130 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 130 | 16 |
| Losartan Potassium | Losartan Potassium | 127 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 126 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 123 | 20 |
| Montelukast Sodium | Montelukast Sodium | 123 | 12 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 116 | 13 |
| Dutasteride | Dutasteride | 115 | 12 |
| Captopril | Captopril | 110 | 14 |
| Midodrine Hcl | Midodrine Hcl | 108 | 11 |
| Multaq | Dronedarone Hcl | 108 | 13 |
| Verquvo | Vericiguat | 106 | 12 |
| Warfarin Sodium | Warfarin Sodium | 98 | suppressed |
| Glimepiride | Glimepiride | 96 | 16 |
| Lisinopril | Lisinopril | 94 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 93 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 88 | 11 |
| Colchicine | Colchicine | 86 | suppressed |
| Digoxin | Digoxin | 85 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 78 | 12 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 77 | 16 |
| Metolazone | Metolazone | 75 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 72 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 68 | suppressed |
| Azithromycin | Azithromycin | 66 | 62 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 63 | suppressed |
| Gabapentin | Gabapentin | 62 | 12 |
| Jentadueto Xr | Linagliptin/Metformin Hcl | 62 | suppressed |
| Finasteride | Finasteride | 61 | 12 |
| Sertraline Hcl | Sertraline Hcl | 60 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 59 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 54 | suppressed |
| Primidone | Primidone | 54 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 53 | suppressed |
| Nexium | Esomeprazole Magnesium | 52 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 50 | suppressed |
| Methimazole | Methimazole | 50 | suppressed |
| Benicar | Olmesartan Medoxomil | 49 | suppressed |
| Dexilant | Dexlansoprazole | 49 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 49 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 48 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 48 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 47 | suppressed |
| Pregabalin | Pregabalin | 47 | suppressed |
| Wegovy | Semaglutide | 47 | 12 |
| Clonidine | Clonidine | 46 | 11 |
| Nystatin | Nystatin | 46 | suppressed |
| Simvastatin | Simvastatin | 44 | suppressed |
| Nateglinide | Nateglinide | 42 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 41 | suppressed |
| Levofloxacin | Levofloxacin | 40 | 32 |
| Torsemide | Torsemide | 40 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 39 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 38 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 38 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 36 | suppressed |
| Mirtazapine | Mirtazapine | 36 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 35 | suppressed |
| Temazepam | Temazepam | 35 | suppressed |
| Corlanor | Ivabradine Hcl | 33 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 32 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 32 | suppressed |
| Kerendia | Finerenone | 32 | suppressed |
| Repaglinide | Repaglinide | 32 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 31 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 30 | 12 |
| Ketoconazole | Ketoconazole | 29 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 29 | suppressed |
| Procrit | Epoetin Alfa | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 28 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 28 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 13 |
| Risedronate Sodium Dr | Risedronate Sodium | 27 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 26 | suppressed |
| Ranolazine Er | Ranolazine | 26 | suppressed |
| Restasis | Cyclosporine | 26 | suppressed |
| Roflumilast | Roflumilast | 26 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 25 | suppressed |
| Crestor | Rosuvastatin Calcium | 25 | suppressed |
| Irbesartan | Irbesartan | 25 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 25 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 25 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 24 | suppressed |
| Folic Acid | Folic Acid | 24 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 23 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 23 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Levemir Flexpen | Insulin Detemir | 22 | suppressed |
| Lubiprostone | Lubiprostone | 22 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Diovan | Valsartan | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 20 |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Alprazolam | Alprazolam | 20 | suppressed |
| Belsomra | Suvorexant | 20 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 20 | suppressed |
| Gemtesa | Vibegron | 19 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 19 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 19 | suppressed |
| Jublia | Efinaconazole | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Benicar Hct | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Calcitriol | Calcitriol | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | suppressed |
| Clotrimazole | Clotrimazole | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Hydrocortisone Butyrate | Hydrocortisone Butyrate | 15 | suppressed |
| Nyamyc | Nystatin | 15 | suppressed |
| Nystop | Nystatin | 15 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 15 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Vytorin | Ezetimibe/Simvastatin | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Exforge | Amlodipine Besylate/Valsartan | 14 | suppressed |
| Exforge Hct | Amlodipine/Valsartan/Hcthiazid | 14 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 14 | suppressed |
| Savaysa | Edoxaban Tosylate | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Uloric | Febuxostat | 13 | suppressed |
| Alogliptin-Metformin | Alogliptin Benz/Metformin Hcl | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Azor | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Enulose | Lactulose | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Micardis | Telmisartan | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Paricalcitol | Paricalcitol | 12 | suppressed |
| Rapaflo | Silodosin | 12 | suppressed |
| Tudorza Pressair | Aclidinium Bromide | 12 | suppressed |
| Zaleplon | Zaleplon | 12 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,108.25 · 162 records | E.R. Squibb & Sons, L.L.C. | ACCRUFER, ACTHAR, AIRSUPRA, AURORA EV-ICD MRI SURESCAN, Actemra, BREZTRI, BRILINTA, Bimzelx, CAMZYOS, CREON, ELIQUIS, EVENITY, FARXIGA, FUROSCIX, Flector, GEMTESA, GENVISC 850 SODIUM HYALURONATE, JARDIANCE, Kerendia, LEQVIO, LINZESS, Licart, LifeVest, MONOVISC, MOUNJARO, MYCARELINK, NEXLETOL, NURTEC ODT, Ozempic, PANCREAZE, PAXLOVID, PEMGARDA, PROLIA, PURIFIED CORTROPHIN GEL, REPATHA, SAPIEN 3 Ultra RESILIA, TRELEGY ELLIPTA, TREMFYA, TRINTELLIX, TRIVISC SODIUM HYALURONATE, Tirosint, Tymlos, UBRELVY, VERQUVO, Veltassa, Wegovy, ZENPEP, ZEPBOUND | 29 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Brilinta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error